A Comprehensive Physicochemical, In Vitro and Molecular Characterization of Letrozole Incorporated Chitosan-Lipid Nanocomplex

Azandaryani, Abbas Hemati; Kashanian, Soheila; Shahlaei, Mohsen; Derakhshandeh, Katayoun; Motiei, Marjan; Moradi, Sajad

doi:10.1007/s11095-019-2597-4

Cited by 30 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The EE% of the samples increased by 2-3% for each Let and Cyclo at the higher lipid: drug and surfactant: cholesterol molar ratios. It was proposed that the thicker bilayer formed was capable of a higher encapsulation capacity for the hydrophobic drugs [32][33][34]. The surfactant: cholesterol molar ratio significantly impacted the size of the niosomes formed, while the combined effect of the surfactant: cholesterol and lipid: drug ratio affected the EE%.…”

Section: Noisome Formulations Propertiesmentioning

confidence: 99%

Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression

et al. 2021

View full text Add to dashboard Cite

Breast cancer is one of the most prevalent causes of cancer mortality in women. In order to increase patient prognosis and survival rates, new technologies are urgently required to deliver therapeutics in a more effective and efficient manner. Niosome nanoparticles have been recently employed as therapeutic platforms capable of loading and carrying drugs within their core for both mono and combination therapy. Here, niosome-based nanoscale carriers were investigated as a targeted delivery system for breast cancer therapy. The platform developed consists of niosomes loaded with letrozole and cyclophosphamide (NLC) and surface-functionalized with a folic-acid-targeting moiety (NLCPFA). Drug release from the formulated particles exhibited pH-sensitive properties in which the niosome showed low and high release in physiological and cancerous conditions, respectively. The results revealed a synergic effect in cytotoxicity by co-loading letrozole and cyclophosphamide with an efficacy increment in NLCPFA use in comparison with NLC. The NLCPFA resulted in the greatest drug internalization compared to the non-targeted formulation and the free drug. Additionally, downregulation of cyclin-D, cyclin-E, MMP-2, and MMP-9 and upregulating the expression of caspase-3 and caspase-9 genes were observed more prominently in the nanoformulation (particularly for NLCPFA) compared to the free drug. This exciting data indicated that niosome-based nanocarriers containing letrozole and cyclophosphamide with controlled release could be a promising platform for drug delivery with potential in breast cancer therapy.

show abstract

Section: Noisome Formulations Propertiesmentioning

confidence: 99%

Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Cancer is the second leading cause of mortality globally after cardiovascular disease. Worldwide, there have been 19.3 million cancer diagnoses, with a death rate of about 10 million instances [1,2]. Cancer treatment options include surgery, radiation therapy, and chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

“…Nanoparticles are coated with a ligand to promote cellular absorption through receptor-mediated endocytosis, which increases the accumulation of medicines in cancer cells [18]. This method relies on the interaction between ligands on the surface of nanoparticles and cell surface receptors of cancer cells [19]. Hyaluronic acid (HA) is a polysaccharide ligand used chiefly for active targeting systems because of its high selectivity and affinity to CD44 receptors highly expressed in different tumor cells [18,20].…”

Section: Introductionmentioning

confidence: 99%

Chitosan–Hyaluronic Acid Nanoparticles for Active Targeting in Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

Cancer is the most common cause of death worldwide; therefore, there is a need to discover novel treatment modalities to combat it. One of the cancer treatments is nanoparticle technology. Currently, nanoparticles have been modified to have desirable pharmacological effects by using chemical ligands that bind with their specific receptors on the surface of malignant cells. Chemical grafting of chitosan nanoparticles with hyaluronic acid as a targeted ligand can become an attractive alternative for active targeting. Hence, these nanoparticles can control drug release with pH- responsive stimuli, and high selectivity of hyaluronic acid to CD44 receptors makes these nanoparticles accumulate more inside cells that overexpress these receptors (cancer cells). In this context, we discuss the benefits and recent findings of developing and utilizing chitosan–hyaluronic acid nanoparticles against distinct forms of cancer malignancy. From here we know that chitosan–hyaluronic acid nanoparticles (CHA-Np) can produce a nanoparticle system with good characteristics, effectiveness, and a good active targeting on various types of cancer cells. Therefore, this system is a good candidate for targeted drug delivery for cancer therapy, anticipating that CHA-Np could be further developed for various cancer therapy applications.

show abstract

“…108 EE values of samples improved by 2-3% for each drug at the greater surfactant:cholesterol and lipid:drug molar proportions. It was suggested that the thicker bilayer could have greater encapsulation potential for hydrophobic drugs, [109][110][111] and also the presence of FA may increase the EE. Additionally, the mean size of the modified NPs was lower than that of the NLC.…”

Section: Niosomal Codelivery Of Two Drugsmentioning

confidence: 99%

Composition, preparation methods, and applications of nanoniosomes as codelivery systems: a review of emerging therapies with emphasis on cancer

Roostaee,

Derakhshani,

Mirhosseini

et al. 2024

Nanoscale

View full text Add to dashboard Cite

show abstract

A Comprehensive Physicochemical, In Vitro and Molecular Characterization of Letrozole Incorporated Chitosan-Lipid Nanocomplex

Cited by 30 publications

References 35 publications

Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression

Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression

Chitosan–Hyaluronic Acid Nanoparticles for Active Targeting in Cancer Therapy

Composition, preparation methods, and applications of nanoniosomes as codelivery systems: a review of emerging therapies with emphasis on cancer

Contact Info

Product

Resources

About